Dongkook Pharmaceutical stock (KR7086450004): Opens first global showroom for Centellian24

Dongkook Pharmaceutical launched its first global showroom for the dermocosmetic brand Centellian24 on May 14, marking a key expansion in its international beauty segment.

Dongkook Pharmaceutical announced the opening of its first-ever global showroom for the dermocosmetic brand Centellian24 on May 14, 2026, at its headquarters. This move highlights the company's push into the growing global skincare market, according to Asiae as of 05/14/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Dongkook Pharmaceutical Co., Ltd.
• Sector/industry: Pharmaceuticals and dermocosmetics
• Headquarters/country: South Korea
• Core markets: Asia, with growing global presence
• Key revenue drivers: Branded generics, skincare products like Centellian24
• Home exchange/listing venue: Korea Exchange (KRX)
• Trading currency: KRW

Dongkook Pharmaceutical: core business model

Dongkook Pharmaceutical focuses on the development, manufacturing, and sale of pharmaceutical products and dermocosmetics. The company offers branded generics, prescription drugs, and over-the-counter skincare lines, with Centellian24 as a flagship brand targeting madecassoside-based skincare. Headquartered in South Korea, it serves domestic and international markets through partnerships and direct sales, as detailed on its official site.

The business model emphasizes innovation in biotech-derived cosmetics alongside traditional pharma, allowing diversification from generic competition. This dual approach supports steady revenue from established drugs while capturing growth in the $150 billion global skincare sector.

Main revenue and product drivers for Dongkook Pharmaceutical

Key revenue comes from pharmaceuticals like anti-inflammatories and antibiotics, supplemented by the fast-growing Centellian24 line, which features products for skin barrier repair. The recent showroom opening on May 14 aims to boost brand visibility for international expansion, per Asiae as of 05/14/2026. Skincare now represents a rising share of sales amid Asia's beauty boom.

Centellian24 has gained traction in Southeast Asia and beyond, driven by K-beauty trends. Dongkook invests in R&D for natural ingredient formulations, positioning it against global players like L'Oréal in the functional cosmetics niche.

Industry trends and competitive position

The dermocosmetics market is expanding at 8-10% annually, fueled by demand for science-backed skincare, according to sector reports. Dongkook's Centellian24 leverages centella asiatica extracts, aligning with clean beauty preferences popular among US consumers via K-beauty imports.

In Korea's competitive pharma landscape, Dongkook differentiates through its cosmetics pivot, competing with the likes of Amorepacific while maintaining pharma stability. US investors track such firms for exposure to Asia's consumer health growth.

Why Dongkook Pharmaceutical matters for US investors

Dongkook offers US investors indirect exposure to South Korea's booming cosmetics export market, valued at over $10 billion annually. With shares listed on KRX and global brand push via Centellian24, it ties into US retail trends where K-beauty sales hit $2.5 billion in 2025.

The company's international showroom signals ambitions beyond Asia, potentially increasing relevance for American portfolios seeking diversified pharma plays with consumer upside.

Conclusion

Dongkook Pharmaceutical's launch of the Centellian24 global showroom on May 14 underscores its strategic shift toward international dermocosmetics growth. Balancing pharma stability with skincare expansion, the company navigates competitive markets effectively. Investors monitor such developments for insights into Asia's consumer trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.